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Characterization and Quantitation of Peptide±MHC
Complexes Produced from Hen Egg Lysozyme
Using a Monoclonal Antibody
Gilles Dadaglio, Christopher A. Nelson, strongly immunogenic in I-Ak±bearing mice (Allen et al.,
1984) and also because the binding of this HEL peptideM. Brian Deck, Shirley J. Petzold,
and Emil R. Unanue 48-62 to I-Ak has been studied extensively (Nelson et
al., 1996a). By a combination of immunoprecipitation,Center for Immunology
Department of Pathology antibody blocking, and T cell inhibition studies, we dem-
onstrate that Aw3.18 binds directly over the peptide-Washington University School of Medicine
St. Louis, Missouri 63110 combining site of I-Ak. This MAb, like both Y-Ae and
30-2, is thought to recognize the same surface of the
peptide±MHC complex recognized by the antigen-spe-
cific receptor of the T cell.Summary
In this study, we used Aw3.18 to examine three issues.
First, we examined the changes in the conformation ofHere we describe generation of Aw3.18, a monoclonal
the peptide±MHC complex after modification of singleantibody that recognizes peptide residues 48±62 of
peptide residues. We show a marked decrease in thehen egg lysozyme (HEL) bound to the MHC class II
immunoreactivity of the complex after changes in themolecule I-Ak. Epitope mapping revealed that Aw3.18
peptide anchor at P1. Second, we examined the effectsdetects a change in the solvent-exposed surface of
of the antibody on T cell recognition of the complex.this peptide±MHC complex upon substitution of the
Only some T cells directed against this peptide±MHCpeptide side chain at position P1. Furthermore, Aw3.18
complex were inhibited by blocking with Aw3.18, andblocked recognition by some, but not all, of the HEL
not others. This suggested that T cell receptors differed48-62±reactive T cell hybridomas tested, suggesting
in their recognition of the complex, with individual T cella heterogeneity in the T cell response toward this com-
receptors recognizing overlapping but distinct regions.plex. Finally, using Aw3.18, it was possible to deter-
Finally, we determined the number of peptide±MHCmine the fraction of I-Ak molecules loaded with 48-62
complexes produced by an antigen-presenting cellpeptide after culture of an antigen-presenting cell in
(APC) exposed to HEL under different antigen-pro-medium containing HEL.
cessing conditions. Only a small fraction of the class II
molecules on the APC could be loaded with peptide byIntroduction
culture in exogenous HEL.
Our understanding of the formation of peptide±major
histocompatibility (MHC) class II complexes, as well as
Resultstheir biological function, has been advanced by the gen-
eration of monoclonal antibodies (MAbs) that recognize
Aw3.18 Recognizes Complexes between the HELspecific peptide±MHC combinations. Two of the best
Peptide 48-62 and the MHC Class II Molecule I-Akcharacterized examples of antibodies that recognize
MAb Aw3.18 was generated by repeated immunizationpeptide±MHC class II complexes are Y-Ae (Murphy et
of CAF-1 mice with M12-Ak 48-62 cells. These cells con-al., 1989) and 30-2 (Eastman et al., 1996). Y-Ae recog-
stitutively express HEL 48-62±I-Ak complexes. The cellsnizes a self I-Ea peptide presented on I-Ab; this MAb
were made by covalently linking the HEL peptide 48-62reacts with between 10% and 15% of the surface I-Ab
to the N-terminus of the I-Abk chain (Viner et al., 1996)molecules on B cells from mice that express both I-Ab
as described by Kappler's laboratory (Ignatowicz et al.,and I-Eb molecules (Murphy et al., 1992). In addition to
1995). Several immunofluorescence experiments indi-making contact with the Ea peptide, Y-Ae is thought to
cated that Aw3.18 binds to HEL peptide±loaded I-Akbind across the top of the I-Ab molecule, interacting with
complexes. First, Aw3.18 recognized the cells used forresidues in both the Aba and Abb a-helical regions. In a
the immunization (M12-Ak 48-62 cells) but showed nosimilar way, MAb 30-2 recognizes a fragment of human
reactivity against cells expressing either unaltered I-Akinvariant chain (CLIP) presented on I-Ab. Roughly 13%
(M12-Ak cells) or I-Ak linked to a different HEL peptideof the surface I-Ab molecules on the human invariant
(M12-Ak 34-45 cells) (Figure 1). These results demon-chain expressing cell line T1-I-Ab can be detected using
strated that Aw3.18 was not specific for I-Ak alone orthis MAb (Eastman et al., 1996).Both of theseantibodies,
for the peptide linker used to make both the M12-AkY-Ae and 30-2, recognize peptide±MHC complexes de-
48-62 and M12-Ak 34-45 cell lines. These results alsorived from endogenously expressed self proteins.
indicated that recognition by Aw3.18 was dependent onWe have developed an antibody specific for a pep-
the presence of the HEL 48-62 peptide.tide±MHC complex produced from an exogenous anti-
We next tested whether Aw3.18 could bind M12-Akgen such that both the amount and delivery of the anti-
mHEL cells. M12-Ak mHEL cells express HEL as a mem-gen to the MHC class II processing pathway could be
brane-bound fusion protein and have been shown tocontrolled. Here we describe generation of Aw3.18, a
process the mHEL for presentation on I-Ak, with a largeMAb that recognizes the hen egg lysozyme (HEL) pep-
fraction of the mHEL being processed into peptidestide 48-62 (DGSTDYGILQINSRW) bound to the MHC
containing 48-62 (Nelson et al., 1997). Aw3.18 detectedclass II molecule I-Ak. This peptide±MHC complex was
selected for study because the HEL 48-62 peptide is the HEL±I-Ak complexes produced by these cells (Figure
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Figure 2. Dose-Dependent Binding of Aw3.18
(A) I-Ak±positive (M12-Ak) or I-Ak±negative (M12.C3) cells were incu-
Figure 1. Aw3.18 Detects HEL 48-62 Peptide±I-Ak Complexes on B bated overnight at 106 cells/ml in the indicated concentrations of
Lymphoma Cells exogenous HEL. The binding of Aw3.18 was detected by flow cyto-
metric analysis as described in Figure 1.Flow cytometricanalysis of cells reactivewith the MAb40F (anti-I-Ak)
(B) The Aw3.18 staining of cells cultured overnight in the differentand Aw3.18. The B lymphoma cell lines expressed either unaltered
concentrations of synthetic peptide, either with HEL 48-62 peptideI-Ak (M12-Ak), I-Ak with a covalently attached HEL 48-62 peptide
(p48-62) or with a control peptide, HEL 34-45 (p34-45). The amount(M12-Ak 48-62), I-Ak with a covalently attached HEL 34-45 peptide
of binding was detected by flow cytometric analysis.(M12-Ak 34-45), or HEL peptide±I-Ak complexes produced from a
For comparison, a 70 mM HEL solution contains approximately 1membrane HEL fusion protein (M12-Ak mHEL). Bold lines represent
mg/ml HEL.data obtained by incubating cells with either biotinylated 40F MAb
or Aw3.18 MAb and then with R-phycoerythrin conjugated to strep-
tavidin; fine lines represent data obtained by incubating cells only tested the ability of Aw3.18 to immunoprecipitate pep-
with the secondary reagent.
tide±I-Ak complexes composed of radiolabeled HEL pep-
tides and purified I-Ak. For this procedure, 125I-labeled
1). Furthermore, this immunofluorescence was not inhib- peptides were bound to detergent-solubilized I-Ak at
ited by inclusion of an excess of HEL 48-62 peptide room temperature and pH 5.5. The newly formed pep-
during the cell staining (data not shown), suggesting tide±I-Ak complexes were separated from the remaining
that the MAb did not recognize free peptide. Aw3.18 unbound peptide by passage through a Spin column.
also recognized complexes formed by feeding exoge- Iodination of the tyrosine at position 53 of HEL 48-61
nous HEL toM12-Ak cells. Dose-dependent MAb binding peptide inhibited Aw3.18 binding (for example, in one
was observed using M12-Ak cells incubated overnight experiment, 40F precipitated 130,800 cpm of peptide±
in different concentrations of HEL (Figure 2A). I-Ak complex, whereas Aw3.18 precipitated only 400
In a similar way, peptide±I-Ak complexes formed from cpm). Therefore, an analog peptide was made in which
synthetic HEL peptide were also detected. Aw3.18 residue53 was changed to phenylalanine and a separate
bound to M12-Ak cells incubated overnight in HEL 48-62 tyrosine was added at theC-terminus. Purified I-Ak mole-
peptide, whereas no staining was observed on M12-Ak cules loaded with this HEL peptide analog, 48-61 F53
cells cultured overnight in control peptide (HEL 34-45, Y62 (DGSTDFGILQINSRY), were immunoprecipitable
Figure 2B). In both cases the staining was dependent with Aw3.18 (Figure 3). Under the conditions used,
on the presence of I-Ak on the APCs. The class II± Aw3.18 immunoprecipitated 67% of the analog pep-
negative cell line (M12.C3) was unable to form the deter- tide±I-Ak complexes, while 40F immunoprecipitated
minant, even after overnight culture in HEL or HEL 48- 85%. The binding was specific. Peptide±I-Ak complexes
62 peptide. made with an irrelevant peptide (HEL 34-45 with a tyro-
sine at the C-terminus, FESNFNTQATNRY) were unreac-
Fine Specificity of Peptide Recognition by Aw3.18 tive with Aw3.18 (40F MAb precipitated 81.5% of the
To determine which of the amino acid side chains on complex containing a total of 54,500 cpm; Aw3.18 pre-
cipitated 0.9%) (Table 1).the HEL peptide are required for Aw3.18 binding, we
Lysozyme±MHC Complex Specific Antibody
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Table 1. Immunoprecipitation of Peptide±I-Ak Complexes
Peptide
Immunoprecipitated
Name Composition with Aw3.18 (% cpm)
48-61 F53, Y62 DGSTDFGILQINSRY* 77
48-61 S52, F53, Y62 - - - - S - - - - - - - - - 28
48-61 N52, F53, Y62 - - - - N - - - - - - - - - 19
48-61 Q52, F53, Y62 - - - - Q - - - - - - - - - 3
48-61 H52, F53, Y62 - - - - H - - - - - - - - - 5
48-61 R52, F53, Y62 - - - - R - - - - - - - - - 7
48-61 T52, F53, Y62 - - - - T - - - - - - - - - 9
48-61 V52, F53, Y62 - - - - V - - - - - - - - - 9
48-61 E52, F53, Y62 - - - - E - - - - - - - - - 14
48-61 C52, F53, Y62 - - - - C - - - - - - - - - 32
48-61 F53, I55, Y62 - - - - - - - F - - - - - - 70
48-61 F53, S55, Y62 - - - - - - - S - - - - - - 65
48-61 F53, F56, Y62 - - - - - - - - F - - - - - 62
48-61 F53, I56, Y62 - - - - - - - - I - - - - - 57
48-61 F53, S56, Y62 - - - - - - - - S - - - - - 51
48-61 F53, K56, Y62 - - - - - - - - K - - - - - 32
48-61 F53, E57, Y62 - - - - - - - - - E - - - - 60
48-61 F53, S57, Y62 - - - - - - - - - S - - - - 84
48-61 F53, N57, Y62 - - - - - - - - - N - - - - 66
48-61 F53, T57, Y62 - - - - - - - - - T - - - - 73
48-61 F53, V57, Y62 - - - - - - - - - V - - - - 73
48-61 F53, T58, Y62 - - - - - - - - - - T - - - 48
48-61 F53, N58, Y62 - - - - - - - - - - N - - - 59
48-61 F53, V58, Y62 - - - - - - - - - - V - - - 49
48-61 F53, R58, Y62 - - - - - - - - - - R - - - 24
48-61 F53, Q60, Y62 - - - - - - - - - - - Q - - 72
48-61 F53, K60, Y62 - - - - - - - - - - - K - - 76
48-61 F53, D60, Y62 - - - - - - - - - - - R - - 77
52-61 F53, Y62 - - - - - - - - - - - - - - 5
31-47 Y48 AAKFESNFNTQATNRNTY* 1
This table summarizes the results obtained by immunoprecipitation of radiolabeled peptide±MHC complexes. The reactions were carried out
as described in the legend to Figure 4 and in Experimental Procedures. Figure 4 shows the results with alanine substitutions. This table
includes other substitutions at residues 52, 55, 56, 57, 58, and 60. Synthetic peptides were made containing the indicated substitutions. The
peptides were labeled with 125I on the C-terminal tyrosine residue as indicated (asterisk). Radiolabeled peptide±class II complexes were made
with each of the indicated peptides and detergent-solubilized I-Ak. The peptide±I-Ak complexes were purified to remove unbound peptide on
P6 Bio-Spin column. The amount of complex which immunoprecipitated with either 40F (anti-I-Ak) or Aw3.18 MAbs was measured and is
presented as the percentage of total complex in the immunoprecipitation reaction; 100% refers to the amount of complexes immunoprecipitated
by mAb 40F, which represented typically about 85% of the total purified I-Ak complex. Included are the results with a shorter peptide, 52-61,
and with an unrelated HEL, peptide 31-45. All reactions contained 50±100,000 cpm of purified peptide±MHC complexes.
Additional synthetic peptides were tested in this
assay. The first set, although similar to the analog HEL
48-61 F53 Y62 peptide, were made by replacing individ-
ual amino acids one at a time with alanine. We previously
showed that the only alanine substitution that affects
binding is substitution of the residue at position 52, the
main P1 anchor (Nelson et al., 1996b). This was also the
case with these analog peptides. The total amount of
complexes formed with the A52-substituted peptide
was much less than that formed with the other substi-
tuted peptides, as expected from our previous studies
(Nelson et al., 1996b) (Table 1). Regardless, since the
label is on the peptide, and a constant number of counts
per minute was added to each reaction (in the form of
purified complexes), the initial level of peptide binding Figure 3. Aw3.18 Immunoprecipitates HEL Peptide±I-Ak Complexes
should not affect the ability of Aw3.18 to precipitate the Peptide±I-Ak complexes were made from 125I-labeled HEL 48-61 F53
Y62 peptide (DGSTDFGILQINSRY) and detergent-solubilized I-Akdifferent complexes.
under standard conditions. The newly formed peptide±I-Ak com-The amino acid side chains in positions 50±53 were
plexes were purified and then incubated with the indicated amountrequired for Aw3.18 binding; alanine replacement of any
of either 40F (anti-I-Ak) or Aw3.18 MAbs. The amount of complexof these amino acids markedly reduced the recognition
that immunoprecipitated with protein A±Sepharose was measured.
of the complex by Aw3.18 (Figure 4A). Alanine substitu- The amount is given as a percentage of the total complex in the
tions of the remaining peptide residues had only a small reaction. Between 50,000 and 100,000 cpm of purified complex was
used for each reaction.effect, yielding at most a 30% drop in antibody binding
Immunity
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Figure 4. Aw3.18 Recognition Is Sensitive to
Changes in the Peptide
(A) Affinity-purified I-Ak molecules incubated
loaded with 125I-labeled peptides contain-
ing the indicated alanine substitutions. The
amount of each complex immunoprecipi-
tated with MAb Aw3.18 was determined and
is given as a percentage of the total complex
precipitated in each reaction with MAb 40F.
(About 80% of the labeled complexes precipi-
tated with 40F, and this was taken as the
100% value.) For comparison, WT represents
complexes made using the HEL 48-61 F53
Y62 peptide. The alanine substitution at posi-
tion 54 was not done (nd) because this resi-
due is a glycine in the WT peptide.
(B) Summary of binding and T cell response
data from previous studies (see Discussion),
representing the putative alignment of the
HEL 48-62 epitope within the binding site of
the class II I-Ak molecule. Numbers represent
the amino acid positions within the HEL mole-
cule; the peptide sequence is given using the
standard single-letter amino acid code. TCR
denotes residues that have been mapped as
T cells receptor contacts. P1, P4, P6, and P9
represent putative anchor residues within the
HEL peptide.
(see the alanine at position 49 and at position 56 in reactivity is the tyrosine at position 53 (Figure 4A). This
tyrosine side chain has been mapped as a T cell contactFigure 4A).
The aspartic acid at position 52 constitutes the pri- and probably points up and away from the class II mole-
cule (Allen et al., 1987). The other T cell contact residuemary anchor residue of the HEL 48-61 peptide, with the
side chain at position 52 thought to point down into in this peptide, the leucine at position 56, had only a
minor influence on Aw3.18 recognition. Taken together,the I-Ak molecule (summarized in Figure 4B). To further
examine Aw3.18 recognition at this position, nine differ- these results demonstrate that Aw3.18 recognizes a por-
tion of the HEL peptide spanning residues 50±53. Thisent amino acid substitutions were made. Each of these
substitutions resulted in complexes that were less pre- constitutes a segment of the portion of the HEL peptide
thought to lie in the peptide-binding groove of the I-Akcipitable with Aw3.18 (S52, N52, Q52, H52, R52, T52,
V52, E52, and C52 in Table 1). Three of these substitu- molecule (Nelson et al., 1996a).
tions had previously been shown to cause less than a
10-fold drop in peptide-binding strength (E52, C52, and Antibody Blocking Studies Map the Aw3.18
Determinant to the Top of the I-Ak MoleculeS52; Nelson et al., 1996b). Furthermore, these three sub-
stitutions caused only a small reduction in the SDS sta- Radiolabeled Aw3.18 binding to cells bearing HEL-pep-
tide±I-Ak complexes was specific and could be inhibitedbility of the resulting peptide±I-Ak complexes: from 96%
stable for the HEL 48-61 peptide, to 78% for the E52 by 20-fold excess of cold Aw3.18 antibody (Figure 5A).
This suggested an approach to determine the locationpeptide, 55% for the C52 peptide, and 48% for the S52
peptide (Nelson et al., 1996b). Yet each of the substitu- of the Aw3.18 binding site. The epitopes recognized by
a number of anti-I-Ak MAbs have been mapped usingtions hindered recognition of the peptide±I-Ak complex
by Aw3.18: from 77% precipitated with 48-61 F53 Y62, class II molecules altered by site-directed mutagenesis.
We tested the ability of four of these MAbs to inhibitto 14% precipitated with E52, 28% precipitated with
S52, and 32% precipitated with C52. Clearly, Aw3.18 Aw3.18 binding: two specific for the Aak chain and two
specific for the Abk chain. These MAbs are each reactivewas sensitive to small changes to the peptide side chain
at the anchor position. for a different epitope on the I-Ak molecule and differ in
their abilities to inhibit Aw3.18 binding. For example, onOne of the other amino acids required for Aw3.18
Lysozyme±MHC Complex Specific Antibody
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Figure 6. Aw3.18 Binds to the Top of the I-Ak Molecule
Schematic representation of the top surface of the class II molecule.
The location of the epitopes recognized by the MAbs 10.3.6.2 and
2A2 are indicated. These antibodies blocked the binding of Aw3.18
to M12 I-Ak mHEL cells (Figure 5B).The Aw3.18 binding site probably
lies between these two epitopes. The class II residues are numbered
according to their position within the I-Ak molecule. On the a chain,
position 44 corresponds to a glutamic acid, position 61 to a gluta-
mine, position 65 to a glutamine, position 68 to an alanine, and
position 71 to a lysine. On the b chain, position 64 corresponds toFigure 5. Aw3.18 Binding Can Be Inhibited by the Anti-I-Ak Antibod-
a glutamine, position 65 to a tyrosine, and position 67 to a glutamicies 10.3.6.2 and 40F
acid. The tyrosine at position 65 on the b chain in the k haplotype(A) The binding of radiolabeled Aw3.18 is specific and can be inhib-
replaces three amino acid residues found in this position in the b,ited by excess cold Aw3.18. In each experiment, 106 cells were
d, and q haplotypes (residues 65±67: proline, glutamic acid, andincubated with 125I-labeled Aw3.18 MAb for 2 hr at 48C, either in the
isoleucine). This difference is caused by a deletion of two residuespresence (1) or in the absence (2) of a 20-fold excess of cold
in the k haplotype. For reference, the glutamic acid at positionAw3.18. The cells then were centrifuged through oil to remove un-
67 in the k haplotype corresponds to the glutamic acid at positionbound antibody. The total cell-associated radioactivity was deter-
69 in the b, d, and q haplotypes.mined by counting the radioactivity of the pellets. Specific binding
to both M12 I-Ak 48-61 and M12 I-Ak mHEL cells was observed.
(B) Four I-Ak specific MAbs were tested for the ability to inhibit
Aw3.18 binding. The antibodies 10.3.6.2 and 2A2 were able to block binding site must lie somewhere between the 10.3.6.2
the binding of Aw3.18 to M12-Ak mHEL cells. As described above, and 2A2 determinants, we conclude that Aw3.18 sits
125I-labeled Aw3.18 binding was measured, either in the absence of
over the peptide-binding cleft, where it can make con-cold inhibitor (-) or in the presence of a 20-fold excess of the indi-
tact with the peptide as well as with both of the a helicescated unlabeled anti-I-Ak antibody.
that make up the top of the I-Ak molecule.
Aw3.18 Blocks T Cell Recognition of HELthe b chain, 10.3.6.2 blocked binding of Aw3.18 to M12-
Ak mHEL cells, whereas 40F did not (Figure 5B). The 48-62±I-Ak Complexes
Since Aw3.18 binds over the top of the I-Ak molecule,determinant recognized by 10.3.6.2 (Ia.17) has been
shown to span I-Abk chain residues 64, 65, and 67 (Ros- we reasoned that it should be possible to use this anti-
body to block recognition of the HEL 48-62 peptide byloniec et al., 1993). The MHC class II structure, based
on the model of Brown et al. (1988) and on the crystal T cell hybridomas. Four T cell hybridomas were tested;
all of them are I-Ak restricted, as demonstrated by thestructure of HLA-DR1 (Brown et al., 1993; Stern et al.,
1994) predicts that these residues are located in the ability of the anti-I-Ak MAb 40F to block their responses
(Figure 7). More Aw3.18 antibody was required to reachmiddle of the a-helical portion of the I-Abk chain (Figure
6). The determinant recognized by MAb 40F centers on the same level of inhibition as seen with 40F, although
Aw3.18 binds with about a 5-fold higher affinity thanresidue 75 of the I-Abk chain (Buerstedde et al., 1988).
On the other side of the combining site, 2A2 blocked 40F (see below). Aw3.18 was able to block HEL 48-62
peptide recognition by the T cell hybridomas 3A9 andbinding, whereas H116 did not. The determinant recog-
nized by 2A2 centers on a-chain residues 61, 65, 68, and ALV48. At the concentration of peptide that stimulated
about 50%, the T cell response was blocked almost71 (Peccoud et al., 1990) although it is also dependent on
residue44 (Wei et al., 1994); these residues are predicted 90% by Aw3.18. This blocking was specific; Aw3.18 did
not block recognition of an unrelated HEL peptide (HELto lie near the middle of the a-helical portion of the I-Aak
chain. The determinant recognized by H116 centers on residues 34±45) by the T cell hybridoma A6A2. Impor-
tantly, Aw3.18 did not inhibit one of the HEL 48-62±residue 75 (Peccoud et al., 1990). Because the Aw3.18
Immunity
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Figure 7. Aw3.18 Is Able to Inhibit Peptide Presentation to Some HEL 48-62±Reactive T Cell Hybridomas
Aw3.18 was tested for the ability to inhibit peptide recognition by three HEL 48-62±specific T hybridomas: 3A9, a type A T cell hybridoma,
and ALV48 and DAV21, two type B T cell hybridomas. For the entire assay, M12-Ak cells were cultured in the indicated concentration of
synthetic HEL 48-62 peptide. The IL-2 produced by each of the T cell hybridomas was measured in the presence of different amounts of the
blocking MAbs. Three different antibodies were used: the anti I-Ak MAb 40F, the anti-HEL 48-62±I-Ak complex MAb Aw3.18, or the control
MAb GIR.208.1.62 (specific for the a chain of the human interferon-g receptor). All three antibodies were isotype matched (IgG1,k). The 40F
mAB inhibited all four of the T cell hybridomas tested, consistent with the knowledge that all four hybridomas are I-Ak restricted. The Aw3.18
MAb inhibited HEL 48-62 presentation to both 3A9 and ALV48 but not to DAV21. A6A2 is specific for residues 34±45 of HEL and was used
as a negative control in this assay. As expected, Aw3.18 did not block presentation of the HEL 34±45 peptide to the A6A2 hybridoma.
specific T cell hybridomas tested, DAV21. Recognition molecules loaded with HEL 48-62 peptide. For example,
in a representative experiment, 106 M12-Ak cells culturedof HEL 48-62 peptide by DAV21 was unaffected by the
presence of Aw3.18 antibody, even though this hybrid- overnight in 1 mg/ml HEL were calculated to bind 50 ng
of Aw3.18 (under conditions of Aw3.18 excess) com-oma was very sensitive to inhibition by 40F.
pared with 550 ng of 40F (under conditions of 40F ex-
cess) (Figure 8). These results indicate that roughly 9%The Number of HEL 48-62±I-Ak Complexes
of the surface I-Ak molecules on these cells had beenProduced under Different Conditions
loaded with HEL 48-62 peptide. This corresponds toBy comparing the performance of Aw3.18 and 40F in a
about 2 3 105 sites occupied from a total of 2.2 3 106quantitative binding analysis, it was possible for the
first time to determine the fraction of cell surface I-Ak class II molecules per cell. In contrast, M12-Ak mHEL
Lysozyme±MHC Complex Specific Antibody
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Figure 8. Aw3.18 Reacts with a Fraction of the Cell Surface I-Ak on HEL-Loaded B Lymphoma Cells
(Top row) Exogenous HEL loading. These results show the concentration dependence of Aw3.18 and 40F binding to M12-Ak cells cultured
overnight with 1 mg/ml of HEL, plotted as the amount of antibody bound after incubation in different amounts of antibody. Both the number
of I-Ak molecules (with 40F) and the number of HEL peptide±I-Ak complexes (with Aw3.18) were determined from the Scatchard plot of the
data shown in the right column. Roughly 9% of the class II molecules were loaded with the HEL peptide in this experiment (50 ng Aw3.18
bound vs. 550 ng 40F bound at antibody excess).
(Second row) For comparison, the number of I-Ak molecules on M12-Ak cells cultured in medium alone was also determined. Culture in HEL
increased the number of class II molecules on the M12-Ak cells, resulting in an increase from 2 3 106 to 2.2 3 106 molecules per cell (490 ng
40F bound without HEL compared to 550 ng bound with HEL).
(Third row) Membrane HEL loading. These results show the binding curves for Aw3.18 and 40F binding performed on M12-Ak 48-62 cells.
About 6% of the surface I-Ak on these cells were loaded with the HEL 48-62 peptide (25 ng of Aw3.18 bound vs. 390 ng of 40F).
(Bottom row) Loading of covalently attached peptide. These results show that the covalent attachment of the HEL 48-62 peptide to the b
chain of the I-Ak molecule resulted in the highest fraction of molecules loaded with the HEL peptide. Although this transfectant expresses
only about 200,000 I-Ak molecules, roughly 40,000 of them (20%) were loaded with the HEL peptide. In these experiments, 106 cells were
incubated with 125I-labeled 40F or 125I-labeled Aw3.18 at 48C for 2 hr and then centrifuged through oil to separate bound antibody from free,
as described in Figure 5. The amount of 40F bound to the class II±negative cell M12.C3 was taken as the nonspecific background (this value
was less than 1% of the specific binding). For Aw3.18, the amount of binding to M12-Ak was taken as the nonspecific background (this value
was also less 1% of the nonspecific background).
cells, which constitutively express and process mem- and 15% of surface I-Ab molecules on B cells from mice
that express both I-Ab and I-Eb molecules) and the num-brane HEL, loaded only about 6% of their surface I-Ak.
This value compares well with the number of Ea pep- ber of CLIP peptide±I-Ab complexes detected by 30-2
(roughly 13% of the surface I-Ab molecules on T1-I-Abtide±I-Ab complexes detected by Y-Ae (between 10%
Immunity
734
Table 2. Quantitation of HEL and Aw3.18 Binding in M12.C3 Cells
Bound to 106 M12.C3 Cells
Molecules of HEL
ng pmol (3 10210)
HEL taken up 662 45.03 2710
Aw3.18 bound at
1 hr 3.1 (3.2, 3.8, 2.4) 0.021 1.3
4 hr 9.0 (9.6, 8.8, 8.6) 0.060 3.6
6 hr 6.8 (7.0, 7.2, 6.1) 0.045 2.7
This table presents the results of three different experiments. M.12-I-Ak cells were incubated with HEL for 30 min and then washed extensively
and chased for 1, 4, and 6 hr, after which they were assayed with 125I-labeled Aw3.18. Shown are the mean values obtained from three
experiments; the individual results of each experiment are given in parenthesis. The amount of HEL taken up was determined from a parallel
aliquot of cells incubated with a mixture of 125I-labeled HEL (z2.5 3 106 cpm) and unlabeled HEL molecules. The mean percentage of HEL
taken up by M12.C3 cells was 0.33%. In column 3 we have estimated that 1 mol of AW3.18 binds to 1 mol of complex.
cells). Covalent attachment of the HEL peptide to the HEL peptide 48-62 rests in the peptide-binding groove
of the I-Ak class II molecule. Aw3.18 recognition is MHCI-Abk chain results in loading of more of the class II
molecules; about 20% of the surface I-Ak molecules on dependent; the antibody binds cells cultured in HEL or
HEL 48-62 peptide, but only if the cells express I-Ak.M12-Ak 48-62 cells contain the HEL peptide. Although
these cells present the largest fraction of peptide-loaded Furthermore, this antibody cannot bind free HEL pep-
tide. Aw3.18 recognition is unaffected by the methodcomplexes, they contain the lowest total number of
complexes because of their lower I-Ak expression (a total used to deliver HEL to the class II antigen-processing
pathway. In addition to binding cells cultured in exoge-of 4 3 104 complexes out of 2 3 105 class II molecules per
cell). It has been reported that covalent attachment of nous HEL, Aw3.18 was able to bind I-Ak±bearing cells
that express HEL as a membrane-bound fusion protein.the Ea peptide to the I-Abb chain results in loading of
35% of the I-Ab molecules on M12 I-Ab cells with the Ea The antibody also was able to bind cells that express
HEL 48-62 peptide covalently attached to the N-termi-peptide (Ignatowicz et al., 1995). The fraction of HEL-
loaded complexes on M12 I-Ak 48-62 cells is lower than nus of the I-Abk chain.
We have identified the amino acid side chains of thethis and may represent a difference in the affinities of
the two peptides for their respective class II molecules HEL peptide required for Aw3.18 recognition. To inter-
pret these data, first it is necessary to discuss how theor may reflect a difference in the amount of invariant
chain expressed by the two M12 subclones (Ignatowicz HEL 48-62 peptide binds to I-Ak. Because HEL 48-62
corresponds to a 15±amino acid, naturally processedet al., 1996). Finally, from the slopes of the Scatchard
plots, it also was possible to determine the relative affini- peptide eluted from the class II molecules of M12-Ak
cells cultured in exogenous HEL (Nelson et al., 1992),ties of the two antibodies. In these experiments, Aw3.18
displayed about a 5-fold higher binding affinity than 40F. this peptide is thought to fill completely the binding cleft
of the class II molecule. Three criteria have been usedIn a different approach, we quantified the efficiency
of processing of the 48-62 epitope as it relates to the to show that the HEL 48-62 peptide uses the aspartic
acid at position 52 as its primary anchor residue, P1:uptake of HEL molecules. M12-Ak cells were pulsed for
30 min with HEL, washed, and then placed in culture. first, alanine substitution of the aspartic acid residue
lowers the ability of this peptide to bind I-Ak; second,At various times later, the amount of Aw3.18 binding
was measured. To determine the total amount of HEL alanine substitution of the aspartic acid residue also
lowers the ability of the peptide to form SDS-stableuptake by the cells, an identical sample was pulsed with
HEL trace labeled with 125I. For the conditions used, complexes with I-Ak; and finally, this aspartic acid resi-
due occurs at the correct distance from the peptide'sabout 662 ng of HEL was taken up by 1 3 106 cells. After
1 hr in culture, the cells expressed enough peptide±I-Ak N-terminus for a P1 anchor (usually the fourth or fifth
position in naturally processed peptides) (Nelson et al.,complex to bind 3.1 ng of Aw3.18. This binding in-
creased to 9.0 ng after 4 hr in culture. This value de- 1996b; 1997). Assuming that the HEL 48-62 peptide
binds in a conformation similar to that described forcreased after 6 hr in culture; the cells could bind only
6.8 ng of Aw3.18 (summarized in Table 2). From that other class II±binding peptides (Stern et al., 1994), then
the P1-anchor side chain at position 52 would be ex-point on, the amount of Aw3.18 binding remained rela-
tively constant (as observed with incubation times of 12 pected topoint down toward the class II molecule. Other
putative anchor residues include the isoleucine at P4,and 24 hr; data not shown). Thus, approximately 1 HEL
molecule out of 753 that entered the cell could be de- the glutamine at P6, and the serine at P9. Two of the
remaining residues, the tyrosine at P2 and the leucinetected as a peptide±I-Ak complex at the cell surface
(3.6 molecules out of 2710, Table 2), with the maximum at P5, should point up and in fact have been mapped
as T cell contacts (Allen et al., 1987; our unpublishedexpression found 4 hr after the HEL pulse.
data, summarized in Figure 4B). It is easy to understand
how loss of the T cell contact residue at P2 by alanineDiscussion
substitution could lower Aw3.18 binding; the tyrosine
53 in this position probably makes direct contact withIn this report, we provide direct evidence that MAb
Aw3.18 recognizes a unique determinant formed when the Aw3.18 antibody. It is harder to understand how a
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substitution at the anchor position P1 could alter Aw3.18 (Viner et al., 1996). These conformations, ªtype Aº and
binding, since this residue should be buried in the class ªtype B,º were defined by comparing the ability of T cell
II molecule. hybridomas to respond to peptide or to native HEL-
Our results demonstrate that recognition by Aw3.18 pulsed cells (type A hybridomas show equal recognition
is dependent on the aspartic acid side chain at P1. It is of HEL and peptide, whereas type B hybridomas recog-
possible that other side chains introduced at this posi- nize peptide but show no or only weak recognition of
tion do not fit well into the P1 pocket (because they do HEL). Of the hybridomas reported here, 3A9 is a type
not have the correct shape, or negative charge, to form A, while bothALV48 and DAV21 are type B. Thus, Aw3.18
a salt bridge with an arginine supplied by the a chain does not discriminate between type A and type B com-
at the bottom of the P1 pocket [Nelson et al., 1996b]). plexes: Aw3.18 blocked recognition by 3A9, a type A
These longer side chains may produce a kink in the hybridoma, as well as that by ALV48, a type B hybrid-
peptide or instead may point up and go over the P1 oma. However, Aw3.18 suggests that there may be two
pocket, where they hinder binding of Aw3.18 directly. sets of type B complexes, only one of which can be
An alternative explanation may be that substitution of inhibited. Clearly, anti-peptide±MHC complex antibod-
the peptide anchor side chain results in an indirect ies will be useful to examine the possibility of subtle
change of the solvent-exposed surface recognized by conformational differences in peptide±MHC complexes.
the antibody. Such an effect has recently been demon- MHC class II±bound peptides are obtained primarily
strated for the human class I molecule HLA B8. Reid from extracellular sources. However, it is possible to
and colleagues have shown that substitution of a single deliver endogenously synthesized antigen to the class
peptide anchor residue can cause not only a shift in the II antigen-processing pathway. For example, HEL ex-
position of the peptide mainchain, but also a shift in the pressed as a soluble, secreted, molecule is efficiently
position of portions of the a1 and a2 helices that flank processed and presented on I-Ak (Brooks et al., 1991).
the peptide-binding groove (Reid et al., 1996). Both ex- Numerous constructs have been used to target HEL to
planations have implications for the recognition of pep- different intracellular locations. HEL, or parts of it, have
tide±I-Ak complexes by T cells. In agreement with these been sequestered in the cytoplasm by removing the
results, we have previously found that the response of leader sequence (Brooks and McCluskey, 1993); tar-
the 3A9 T cell hybridoma (which is directed to 48-62) geted to endosomes as fusion protein with invariant
required 50 times more of the peptide mutated at residue
chain (Sanderson et al., 1995) or the class II b chain
52 (aspartic acid replaced by glutamic acid) than of the
(Viner et al., 1996); retained in the endoplasmic reticulum
wild type, in order to elicit a comparable response (our
by addition of a KDEL sequence (Brooks et al., 1991);
unpublished data). Along these lines, previous studies
sorted to lysosomes or endosomes by fusion with ca-
have indicated that changes in MHC anchor residues
thepsin D (Parra-Lopez et al., 1997); and tethered to the
affected T cell responses (Reay et al., 1994; Evavold et
cell surface by addition of a MHC class I transmembraneal., 1993; Kersh and Allen, 1996). The failure of Aw3.18
domain (Nelson et al., 1997). Unfortunately, it has provento bind after changes in the HEL peptide anchor residue
difficult to determine the relative efficiencies of the pro-establishes that the overall conformation of this pep-
cessing at these different intracellular locations. Pre-tide±MHC complex is influenced by changes at this an-
viously, we estimated that fewer than 100 peptide±MHCchor position.
complexes were required to trigger a HEL specific T cellAntibody blocking studies map the determinant rec-
hybridoma (Harding and Unanue, 1990). In this study,ognized by Aw3.18 to the top of the I-Ak molecule. This
the M12-Ak mHEL cells expressed roughly 1.2 3 105antibody binds in a way remarkably similar to that pre-
complexes loaded with HEL 48-62 peptide, while theviously described for Y-Ae and 30-2. In addition to the
M12-Ak 48-62 cells expressed roughly 4 3 104. Becausepeptide, Aw3.18 probably contacts both of the a-helical
these transfectants express very high numbers of pep-regions that make up the sides of the peptide-binding
tide±MHC complexes, it is difficult to design experi-cleft, binding in the same region of the class II molecule
ments based on a T cell hybridoma readout that canthought to be recognized by the antigen-specific recep-
determine which transfectant expresses the most com-tor of the T cell (Garcia et al., 1996). Therefore, it was not
plexes. Attempts to titer the number of APCs provesurprising to find that Aw3.18 could block HEL peptide
uninformative because so few APCs are required forrecognition by two of the I-Ak±restricted T cell hybrido-
maximal activation in each well. In these assays, it ismas tested in this study. More puzzling was the inability
the amount of T cell±APC contact that becomes limitingof Aw3.18 to block HEL 48-62 recognition by the T cell
upon titration and not the number of peptide±MHC com-hybridoma DAV21. It is possible that the number of pep-
plexes. Aw3.18 represents a step forward in this typetide±MHC complexes required to trigger DAV21 is small,
of analysis by allowing a direct comparison of the num-and the Aw3.18 does not have sufficient affinity to re-
ber of complexes displayed at the cell surface.duce this number below the threshold number needed
This study represents the first time that the relativefor triggering. However, the ease with which 40F inhibits
efficiency of a processing event has been measuredthe DAV21 hybridoma argues against this interpretation.
directly. Here we report the number of complexes pro-Still, we find it unlikely that the DAV21 T cell receptor
duced from an exogenous antigen after processing byrecognizes a region of the peptide±MHC complex free
an APC. We found that only 9% of the total class IIfrom overlap with the Aw3.18 binding site. These results
molecules on the surface of the APC (M12 I-Ak) con-suggest that individual T cell receptors differ in their
tained the HEL 48-62 peptide, even after overnight cul-recognition of this peptide±MHC complex.
ture in 1 mg/ml of exogenous HEL. The average half-We previously demonstrated that the HEL 48-62 pep-
tide can bind to I-Ak in more than one conformation life of the class II molecules in these cells is between
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is also I-Ak restricted but is specific for residues 34-45 of HEL (Lam-12 and 15 hr (Nelson et al., 1994), suggesting that at
bert and Unanue, 1989).least half of the surface I-Ak on these cells should have
been formed during the HEL pulse. This relatively low
Generation of the Aw3.18 MAb
fraction of class II loading cannot be explained by disso- Aw3.18 (IgG1,k) was generated by repeated immunization of CAF-1
ciation of the HEL peptide from the I-Ak molecule during mice with M12 I-Ak 48-62 cells. The mice were immunized at 2-week
the experiment. We previously have shown that the HEL intervals for a total of four times by intraperitoneal injection of 2 3
107 cells in 500 ml of phosphate-buffered saline (PBS). A final boost48-62 peptide, on M12 I-Ak cells in culture, remains
of 1 3 107 cells in 200 ml of saline was performedby tail vein injectionbound to the I-Ak molecule (actually extending the half-
3 days before fusion. Spleen cells from the immunized mice werelife of the I-Ak molecules to greater than 40 hr [Nelson
fused with the myeloma P3X63.Ag8 at a ratio of 1:1 using polyethyl-
et al., 1994]). Here we found that culture in 5 mg/ml HEL ene glycol 1500 (Boehringer Mannheim, Indianapolis, IN) following
converted only 1 of 750 HEL molecules internalized into the manufacturer's suggested procedure except that at the end the
a peptide±I-Ak complex (Table 2). These results imply cells were resuspended in 300 ml of DMEM containing 13 HAT,
10% FCS, and 300 ng/ml of cyclosporin A. The final cell suspensionthat only a fraction of the class II molecules on an APC
was plated at 100 ml/well in 30 separate 96-well plates containingmay be accessible for loading with a single epitope from
2 3 104 peritoneal exudate cells (PECs) per well. The PECs werean exogenous antigen. Furthermore, the M12-Ak mHEL
obtained from the peritoneal cavity of B10.BR mice injected 4 days
cells indicate that there may be an upper limit to the earlier with 1.5 ml of thioglycolate media. The PECs were irradiated
fraction of class II that can be loaded, even when the with 2000 rad before plating. After HAT selection, supernatant from
antigen is continuously delivered as an endogenously each well was screened by flow cytometry. In a 96-well V-bottom
plate, between 5 3 105 and 106 CHO-Ak 48-62 cells were incubatedexpressed protein. It is possible that not all of the inter-
with 100 ml of supernatant for 1 hr at 48C. After two washes withnalized HEL molecules end up in the class II loading
medium the cells were incubated for an additional 40 min in 100 mlcompartment. There may exist separate pathways for
of 5 mg/ml R-phycoerythrin±conjugated goat anti-mouse IgG (Mo-
MHC class II loading. The inefficiency also may be due lecular Probes, Eugene, OR). The cells were analyzed on a Becton
to competition by peptides derived from other proteins Dickinson FACSCAN flow cytometer using Cell Quest Software
or due to competition by peptides derived from other (Becton Dickinson, Mountain View, CA). Positive cultures were sub-
cloned twice by limiting dilution in 96-well plates. Of roughly 1000regions of HEL (for example, residues 34±45). The cause
growth-positive clones tested, only one MAb was recovered specificof this apparent inefficiency remains a topic for further
for the HEL peptide in I-Ak. Aw3.18 protein was purified by high-study.
salt elution on protein A±Sepharose for use in these studies.
Analysis by Flow CytometryExperimental Procedures
Approximately 5 3 105 cells were incubated for 1 hr at 48C with 100
ml of biotinylated MAb diluted to 2±10 mg/ml final concentrations inMice, MAbs, and Cell Lines
medium (DMEM, 5% FCS, 0.1% sodium azide). Cells were washedCAF1 mice (H-2kxd) and B10.BR (H-2k) mice were obtained from the
twice in staining medium and then incubated for 40 min at 48C inJackson Laboratory (Bar Harbor, ME). Anti-I-Ak MAb 40F (Pierres et
100 ml streptavidin, R-phycoerythrin conjugate (Molecular Probes,al., 1981), 10±3.6.2 (Oi et al., 1978), 2A2 (Beck et al., 1986), and H116
Eugene, OR) at 5 mg/ml. Cells were analyzed on a FACSCAN flow(Hammerling et al., 1979) were affinity purified from tissue culture
cytometer using Cell Quest software (Becton Dickinson). A total ofsupernatants on protein A±Sepharose.
10,000 cells per sample were analyzed, and the viable cells wereAll of the B lymphoma lines described in this studyÐM12.C3
gated by light scatter.(Glimcher et al., 1985), M12-Ak (Wade et al., 1989), M12-Ak 48-62
and M12-Ak 34-45 (Viner et al., 1996), and M12-Ak mHEL (Nelson et
Peptidesal., 1997)Ðwere cultured in Dulbecco's minimal essential medium
The peptides used in this study were synthesized using FMOC(DMEM) supplemented with 5% fetal calf serum (FCS). M12-Ak 48-62
chemistry on a Synergy 432A peptide synthesizer (Applied Biosys-and M12-Ak 34-45 were created in our laboratory (following the
tems, Foster City, CA) and purified by C18 reverse-phase high-example of Ignatowicz et al., 1995). In brief, M12.C3 cells were
performance liquid chromatography. The accuracy of each peptidetransfected with plasmid encoding a wild-type I-Aka chain and an
synthesis was checked by mass spectrometry. The peptides wereI-Abk chain with an N-terminal insertion coding for an attached HEL
radiolabeled with 125I on the included tyrosine residues by the chlora-48-62 peptide (M12-Ak 48-62 cells) or an attached HEL 34-45 peptide
mine T method (Nelson et al., 1996b).(M12-Ak 34-45 cells). Both constructs used the same linker on the
N-terminus of the Abk chain and result in constitutive occupation of
a fraction of the surface expressed I-Ak with HEL peptide. Automated Cell-Binding Assays with 40F and Aw3.18
The MAbs were radioiodinated using the chloramine T method, typi-sequencing of I-Abk 48-62 protein purified from M12-Ak 48-62 cells
indicates that the majority of the mature protein starts with the cally to a specific activity of 1.3 3 106 cpm/mg. For the binding
reaction, 106 cells were suspended in a total volume of 200 ml ofN-terminal sequence GNSERSGT-DGSTDYGILQINSRWGGGGSLVP
RGSGGGGS-Abk chain. The CHO-Ak 48-62 cell lines used in the PBS containing 5 mM HEPES buffer and 1% bovine serum albumin.
The cells were incubated with 125I-labeled 40F or Aw3.18 MAb atscreen for the Aw3.18 antibody were created by transfection of CHO
cells (ATCC CCL 61) with the same constructs used to make the different concentrations for 2 hr at 48C. To separate the cell-bound
MAb from the excess free MAb, the cells were centrifuged throughM12-Ak 48-62 cell line. M12-Ak mHEL cells were made in our labora-
tory (following the example of Brooks et al., 1991). A cDNA encoding 200 ml of oil (60% dibutyl phtalate, 40% dioctyl phtalate) in a micro-
fuge at 5000 rpm for 4 min. For the 40F MAb, nonspecific bindingthe entire HEL sequence was joined in-frame to a genomic portion
of the MHC class I H-2Ld gene encoding a connecting stalk, a trans- was taken as the amount of antibody bound to the I-Ak±negative
cell line M12.C3 under identical conditions (usually about 1%). Formembrane region, and a complete cytoplasmic domain. This con-
struct was transfected into M12-Ak cells, resulting in expression of the Aw3.18 MAb, the nonspecific background was taken as the
amount of antibody bound by the HEL-negative cell line M12-Aka membrane HEL fusion protein. The I-Aak and I-Abk cDNAs used
for these constructs were originally provided as generous gifts from under identical conditions. The ability of different anti-I-Ak MAbs to
inhibit Aw3.18 binding was assayed using this method (Figure 5).Dr. Ronald N. Germain (National Institutes of Health, Bethesda, MD).
In this study, four T cell hybridomas were used. Three of these The binding of iodinated Aw3.18 was determined after incubation
in the presence of 20-fold excess of unlabeled competitor MAb.were I-Ak restricted and specific for residues 48-62 of HEL: a type
A hybridoma, 3A9 (Allen et al., 1984), and two type B hybridomas For the experiment shown in Table 2, 5 3 106 M12-Ak cells were
incubated for 30 min in 200 ml of DMEM, 5% FCS that contained 5ALV48 and DAV21 (Viner et al., 1996). The fourth hybridoma, A6A2,
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mg/ml of HEL. The cells were then washed extensively and cultured Brooks, A., Hartley, S., Kjer-Nielsen, L., Perera, J., Goodnow, C.C.,
Basten, A., and McCluskey, J. (1991). Class II-restricted presentationat 106 cells/ml for various periods of time. Aliquots were then titrated
of an endogenously derived immunodominant T-cell determinant offor Aw3.18 binding, as described above. To calculate the total HEL
hen egg lysozyme. Proc. Natl. Acad. Sci. USA 88, 3290±3294.uptake by these cells, aliquots were incubated with 125I-labeled HEL
and labeled by the chloramine T method (500 mg of HEL was labeled Brooks, A.G., and McCluskey, J. (1993). Class II-restricted presenta-
with 0.5 mCi). tion of a hen egg lysozyme determinant derived from endogenous
antigen sequestered in the cytoplasm or endoplasmic reticulum of
the antigen presenting cells. J. Immunol. 150, 3690±3697.Immunoprecipitation of Peptide±I-Ak Complexes
Solubilized I-Ak was affinity purified from detergent-lysed T2-Ak cells Brown, J.H., Jardetzky, T., Saper, M.A., Samraoui, B., Bjorkman,
(a gift from Dr. P. Cresswell; Riberdy and Cresswell, 1992) using the P.J., and Wiley, D.C. (1988). A hypothetical model of the foreign
anti-I-Ak MAb 40F as described (Nelson et al., 1996b). This purified antigen binding site of class II histocompatibility molecules. Nature
I-Ak was incubated with 125I-labeled peptide as described (Nelson 332, 845±850.
et al., 1996b). Usually we incubated 25 pmol of I-Ak with 100 pmol Brown, J.H., Jardetzky, T.S., Gorga, J.C., Stern, L.J., Urban, R.G.,
of radiolabeled peptide (100±500,000 cpm) at pH 5.5 for 48 hr. After Strominger, J.L., and Wiley, D.C. (1993). Three-dimensional structure
72 hr at room temperature the peptide±I-Ak complexes were centri- of the human class II histocompatibility antigen HLA-DR1. Nature
fuged through a P6 Bio-Gel Bio-spin column (Bio-Rad Laboratories, 364, 33±39.
Hercules, CA) preequilibrated with PBS containing 1% Triton X100
Buerstedde, J-M., Pease, L.R., Bell, M.P., Nilson, A.E., Buerstedde,
to remove unbound peptide. For each set of isolated complexes,
G., Murphy, D., and McKean, D.J. (1988). Identification of an immu-
50,000±100,000 cpm were incubated in a final volume of 100 ml of
nodominant region on the I-A b chain using site-directed mutagene-
PBS containing 1% Triton X100. For the experiments using the
sis and DNA-mediated gene transfer. J. Exp. Med. 167, 473±487.
amino acid±substituted peptides, 10 mg of 40F or 75 mg of Aw3.18
Eastman, S., Deftos, M., DeRoos, P.C., Hsu, D.H., Teyton, L.,was incubated with each set of complexes. After 2 hr at 48C, 50 ml
Braunstein, N.S., Hackett, C.J., and Rudensky, A. (1996). A study ofof a 50% slurry of protein G±Sepharose in PBS containing 1% Triton
complexes of class II invariant chain peptide: major histocompatibil-X100 was added to each sample. The mixture was incubated for an
ity complex class II molecules using a new complex-specific mono-additional 1 hr at 48C. Bound complexes were separated from free
clonal antibody. Eur. J. Immunol. 26, 385±393.by centrifugation through oil (60% dibutyl phtalate, 40% dioctyl
Evavold, B.D., Sloan-Lancaster, J., Hsu, B.L., and Allen, P.M. (1993).phtalate). The amount of radioactivity in both the pellet and the
Separation of T helper 1 clone cytolysis from proliferation and lym-supernatant was measured. The data are expressed as a percentage
phokine production using analog peptides. J. Immunol. 150, 3131±of the counts per minute immunoprecipitated, calculated as follows:
3140.cpm obtained in the pellet/total cpm 3 100. The background repre-
sents the percentage obtained in the pellet without antibodies and Garcia, K.C., Degano, M., Stanfield, R.L., Brunmark, A., Jackson,
varied from 1.0% to 7.6% of the input counts per minute. M.R., Peterson, P.A., Teyton, L., and Wilson, I.A. (1996). An alpha
beta T cell receptor structure at 2.5 A and its orientation in the TCR-
MHC complex. Science 274, 209±219.Inhibition of T Cell Presentation
The MAbs 40F (IgG2a), Aw3.18 (IgG1,k), and GIR.208 (IgG1,k) as Glimcher, L.H., McKean, D.J., Choi, E., and Seidman, J.G. (1985).
control antibody were tested for their ability to inhibit T cell stimula- Complex regulation of class II gene expression: analysis with class
tion of I-Ak±restricted T cell hybridomas specific for HEL. GIR208 is II mutant cell lines. J. Immunol. 135, 3542±3549.
specific for the a chain of the human interferon-g receptor. In brief, Hammerling, G., Hammerling, U., and Lemke, H. (1979). Isolation of
5 3 104 M12-Ak cells were incubated with 1 3 105 T hybridoma cells twelve monoclonal antibodies against Ia and H2 antigens: serologi-
for 18 hr at 378C in 200 ml of DMEM, containing 5% FCS and the cal characterization and reactivity with B and T lymphocytes. Immu-
indicated amount of HEL peptide. Different amounts of each of the nogenetics 14, 433±439.
MAbs were tested for their ability to interfere with this interaction. Harding, C.V., and Unanue, E.R. (1990). Quantitation of antigen-
The culture supernatants were assayed for interleukin-2 (IL-2) con- presenting cell MHC class II/peptide complexes necessary for T-cell
tent by testing their ability to maintain the growth of an IL-2± stimulation. Nature 346, 574±576.
dependent indicator line (CTLL-2), as measured by [3H]thymidine
Ignatowicz, L., Winslow, G., Bill, J., Kappler, J., and Marrack, P.incorporation.
(1995). Cell surface expression of class II MHC proteins bound by
a single peptide. J. Immunol. 154, 3852±3862.
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